2012-2023
Research Papers (scroll down for reviews and book chapters)
Juarez D, Buono R, Matulis SM, Gupta VA, Duong M, Yudiono J, Paul, M, Mally, S, Diep, S, Hsin, P, Lu, A, Suh, SM, Dong, VM, Roberts, AW, Leverson, JD, Jalaluddin, M, Liu, Z, Bueno, OF, Boise, LH, Fruman, DA. Statin-induced mitochondrial priming sensitizes multiple myeloma cells to BCL2 and MCL-1 inhibitors. 2023; Cancer Research Communications, 3: 2497-2509. PMCID: PMC10704957
Paul, M, Fruman, DA. The road less traveled: Activating an oncogenic kinase. 2023. Trends in Pharmacological Sciences, 44:640-642
Glaviano, S, Foo, ASC, Lam, HY, Yap, KCH, Jacot, W, Jones, RH, Eng, H, Nair, MG, Makvandi, P, Geoerger, B, Kulke, MH, Baird, RD, Prabhu, JS, Carbone, D, Pecoraro, C, Teh, DBL, Sethi, G, Cavalieri, V, Lin, KH, Javidi-Sharifi, NR, Toska, E, Davids, MS, Brown, JR, Diana, P, Stebbing, J, Fruman, DA, Kumar, AP. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. 2023. Molecular Cancer, 22:138. PMCID: PMC10436543
Niman, S, Buono, R, Fruman, DA, Vanderwal, C. Synthesis of a Complex Brasilicardin Analogue Utilizing a Cobalt-Catalyzed MHAT-Induced Radical Bicyclization Reaction. 2023. Organic Letters, 25: 3451-3455. PMCID: PMC10204089
Bardwell, AJ, Paul, M, Yoneda, KC, Andrade-Ludena, MD, Nguyen, OT, Fruman, D, Bardwell, L. The WW domain of IQGAP1 binds directly to the p110a catalytic subunit of PI 3-kinase. 2023. Biochemical Journal, 480: 729–750. PMCID: PMC10625650
Finicle, BT, Eckenstein, KH, Revenko, AS, Anderson, BA, Wan, WB, McCracken, AN, Gil, D, Fruman, DA, Hanessian, S, Seth, PP, Edinger, AL. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics. 2023. Nucleic Acids Research, 51: 1583-1599. PMCID: PMC9976930
Mohammad, SN, Choi, YS, Chung, YJ, Cedrone, E, Neun, BW, Dobrovolskaia, MA, Yang, X, Guo, W, Chew, YP, Kim, J, Baek, SG, Kim, IS, Fruman, DA, Kwon, YJ. Nanocomplexes of doxorubicin and DNA fragments for efficient and safe cancer chemotherapy. 2023. Journal of Controlled Release, 354: 91-108.
Vo, TT, Herzog, L, Buono, R, Lee, JS, Mallya, S, Duong, MR, Thao, J, Gotesman, M, Fruman, DA. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. 2021. Scientific Reports, 11: 21689.
Lee, BJ, Mallya, S, Dinglasan, N, Fung, A, Nguyen, T, Herzog, L, Thao, J, Lorenzana, EG, Wildes, D, Singh, M, Smith, JA, Fruman, DA. Efficacy of novel bi-steric mTORC1 inhibitor in models of B-cell acute lymphoblastic leukemia. 2021. Frontiers in Oncology, Epub Aug 2. PMCID: PMC8366290
Chiu*, H, Buono*, R, Jackson, LV, Herzog, L, Mallya, S, Conn, C, Ruggero, D, Fruman, DA. Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. 2021. iScience, ePub June 16. * Equal contributions. PMCID: PMC8261676
Herzog, L, Walters, B, Lee, JS, Chiu, H, Mallya, S, Fung, A, Nguyen, N, Li, B, Pinkerton, AB, Jackson, MR, Schneider, RJ, Ronai, ZA, Fruman, DA. Targeting eIF4F Translation Initiation Complex with SBI-756 Sensitizes B Lymphoma Cells to Venetoclax. 2021. Br. J. Cancer, 124: 1098–1109. PMCID: PMC7960756
Meli, VS, Atcha, H, Veerasubramanian, PK, Nagalla, R, Luu, TU, Chen, EY, Guerrero-Juarez, CF, Yamaga, K, Pandori, W, Hsieh, JY, Downing, TL, Fruman, DA, Lodoen, MB, Plikus, MV, Wang, W, Liu, WF. YAP-mediated mechanotransduction tunes the macrophage inflammatory response. 2020. Sci. Adv., 6: eabb8471. PMCID: PMC7717914
Ishak Gabra, MB, Yang, Y, Li, H, Senapati, P, Hanse, EA, Lowman, XH, Tran, TQ, Zhang, L, Doan, LT, Xu, X, Schones, DE, Fruman, DA , Kong, M. Dietary glutamine supplementation suppresses epigenetically-activated oncogenic pathways to inhibit melanoma tumour growth. 2020. Nat. Comm., 11: 3326 PMCID: PMC7335172
Ko, TK, Javed, A, Lee, KL, Pathiraja, TN, Liu, X, Malik, S, Soh, SX, Heng, XT, Takahashi, N, Tan, JH, Bhatia, R, Khng, AJ, Chng, WJ, Sia, YY, Fruman, DA, Ng, KP, Chan, ZE, Xie, KJ, Hoi, Q, Chan, C, Teo, AS, Velazquez, O, Meah, WY, Khor, CC, Ong, CT, Soon, WW, Tan, P, Ng, PC, Chuah, C, Hillmer, AM, Ong, ST. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. 2020. Blood, 135: 2337-2353.
Chiu, H, Jackson, LV, Oh, KI, Mai, A, Ronai, ZA, Ruggero, D, Fruman, DA. The mTORC1/4E-BP/eIF4E Axis Promotes Antibody Class Switching in B Lymphocytes. 2019. J. Immunol., 202: 579-590. PMCID: PMC6324996
Lee, JS, Roberts, A, Vo, TT, Juarez, D, Bhatt, S, Bellin, RJ, Agarwal, SK, Salem, AH, Xu, T, Jia, J, Li, L, Hanna, JR, Davids, MS, Fleischman, AG, O’Brien, S, Lam, LT, Leverson, JD, Letai, A, Schatz, J, Fruman, DA. Statins enhance efficacy of venetoclax in blood cancers. 2018. Sci. Transl. Med., Jun 13;10(445). PMCID: PMC6336198
Gotesman, M, Vo, TT, Herzog, L, Tea, T, Mallya, S, Tasian, SK, Konopleva, M, Fruman, DA. mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL. 2018. Oncotarget, 9: 6562-6571. PMCID: PMC5814232
Zhang, Q, Shi, C, Han, L, Jain, N, Roberts, KG, Ma, H, Cai, T, Cavazos, A, Tabe, Y, Jacamo, RO, Mu, H, Zhao, Y, Wang, J, Wu, SC, Cao, F, Zeng, Z, Zhou, J, Mi, Y, Jabbour, EJ, Levine, R, Tasian, SK, Mullighan, CG, Weinstock, DM, Fruman, DA, Konopleva, M. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia. 2018. Oncotarget,9: 8027-8041. PMCID: PMC5814279
Karimzadeh, A., Scarfone, VM, Varady, E, Chao, C, Grathwohl, K, Fathman, JW, Fruman, DA, Serwold, T, Inlay, MA. The CD11a and Endothelial Protein C receptor marker combination simplifies and improves the purification of mouse hematopoietic stem cells. 2018. Stem Cells Transl. Med., 7: 468-576. PMCID: PMC5980368
Chiu, H, Mallya, S, Nguyen, P, Mai, A, Winkler, DG, McGovern, K, Kutok, JL, Fruman, DA. The selective PI3K p110d inhibitor IPI-3063 potently suppresses B cell survival, proliferation and differentiation. 2017. Front. Immunol., 8: 747. PMCID: PMC5491903
Vo, TT, Lee, JS, Nguyen, D, Lui, B, Pandori, W, Khaw, A, Mallya, S, Lu, M, Müschen, M, Konopleva, M, Fruman, DA. mTORC1 inhibition induces resistance to methotrexate and 6-mercaptopurine in Ph+ and Ph-like B-ALL. 2017. Mol. Cancer Therap., Epub May 31. PMCID: PMC5619649
Deng, C, Lipstein, MM, Scott, L, Serrano, XO, Mangone, MA, Li, S, Vendome, J, Hao, Y, Xu, X, Deng, SX, Realubit, RB, Tatonetti, NP, Karan, C, Lentzsch, S, Fruman, DA, Honig, B, Landry, DW, O’Connor, OA. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kdelta and CK1epsilon in hematological malignancies. 2016. Blood, 129: 88-99. PMCID: PMC5216267
Pai, C, Walsh, CM, Fruman, DA. Context-specific function of S6K2 in helper T cell differentiation. 2016. J. Immunol., 197: 3049-58. PMCID: PMC5101169
Hong, CA, Cho, SK, Edson, JA, Kim, J, Ingato, D, Pham, B, Chuang, A, Fruman D, Kwon, YJ. Viral/Nonviral chimeric nanoparticles to synergistically suppress leukemia proliferation via simultaneous gene transduction and silencing. 2016. ACS Nano, 10:8705-14.
Zeng, Z, Wang, RY, Qiu, YH, Mak, DH, Coombes, K, Yoo, SY, Zhang, Q, Jessen, K, Liu, Y, Rommel, C, Fruman, DA, Kantarjian, HM, Kornblau, SM, Andreeff, M, Konopleva, M. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells. 2016. Oncotarget, 7: 55083-97.
So, L, Lee, J, Palafox, M, Mallya, S, Woxland, C, Arguello, M, Truitt, M, Sonenberg, N, Ruggero, D, Fruman, DA. The 4E-BP/eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. 2016. Science Signaling, 9: ra57. Link to Full Text by publisher
Lee, JS, Tang, SS, Ortiz, V, Vo, TT, Fruman, DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. 2015. Oncotarget, 6: 35202-17.
Beagle, BR, Nguyen, D, Mallya, S, Tang, SS, Lu, M, Zeng, A, Konopleva, M, Vo, TT, Fruman, DA. mTOR inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells. 2015. Oncotarget, 6: 2088-100.
Limon, JJ, So, L, Jellbauer, S, Chiu, H, Corado, J, Sykes, S, Raffatellu, M, Fruman, DA. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. 2014. PNAS, 111:E5076-85.
Yea, SS, So, L, Mallya, S, Lee, J, Rajasekaran, K, Malarkannan, S, Fruman, DA. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. 2014. PLOS ONE, 9(6): e99486.
Zhang, Z, Eckert, MA, Ali, MM, Liu, L, Kang, DK, Chang, E, Pone, EJ, Sender, L, Fruman, DA, Zhao, W. DNA-Scaffolded Multivalent Ligands to Modulate Cell Function. 2014. ChemBioChem, 15:1268-73.
Mallya, S, Fitch, BA, Lee, JS, So, L, Janes, MR, Fruman, DA. Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. 2014. PLOS ONE, 9(2): e88865.
Zhang, Z, Ali, MM, Eckert, MA, Kang, DK, Chen, YY, Sender, L, Fruman, DA, Zhao, W. A polyvalent aptamer system for targeted drug delivery. 2013. Biomaterials. 34:9728-35.
Lim, S, Saw, J, Zhang, M, Janes, MR, Lim, AQ, Chang, CT, Fruman, DA, Rizzieri, DA, Tan, SY, Fan, H, Chuah, CTH, Ong, ST. Targeting of the MNK-eIF4E axis in blast crisis chronic myelogenous leukemia inhibits leukemia stem cell function. 2013. PNAS Plus, 110: E2298-307.
So, L, Yea, SS, Oak, JS, Manmadhan, A, Ke, QH, Janes, MR, Kessler, L, Kucharski, J, Li, LS, Martin, MB, Ren, P, Jessen, K, Rommel, C, Fruman, DA. Selective inhibition of phosphoinositide 3-kinase p110a preserves lymphocyte function. 2013. J. Biol. Chem., 288: 5718-31.
Janes, MR, Vu, C, Mallya, S, Shieh, M, Limon, JJ, Lilly, MB, Sender, L, Si, LS, Martin, MB, Ren, P, Liu, Y, Rommel, C, Fruman, DA. Efficacy of the mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. 2013. Leukemia, 27: 586-94.
Review Articles, Commentaries, and Book Chapters
Buono, R, Alhaddad, M, Fruman, DA. Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia. 2023; 14 April. Oncol., 13: 1162694. doi: 10.3389/fonc.2023.1162694
Juarez D, Fruman, DA. Targeting the mevalonate pathway in cancer. 2021. Trends in Cancer, 7: 525-540. PMCID: PMC1662654
Adefemi, N, Fruman, DA, Marshall, AJ. A case for phosphoinositide 3-kinase-targeted therapy for infectious disease. 2020. J. Immunol., 205: 3237-3245.
Fruman, DA. Targeting PI3Kgamma in non-Hodgkin’s lymphoma. 2019. J. Clin. Oncol., 37: 932-934.
Fruman, DA, Chiu, H, Hopkins, BD, Bagrodia, S, Cantley, LC, Abraham, RT. The PI3K pathway in human disease. 2017. Cell, 170: 605-635.
Fruman, DA, O’Brien, S. A targeted treatment with off-target risks. 2017. Nature, 542: 424-5.
Lee, JS, Vo, TT, Fruman, DA. Targeting mTOR for the treatment of B cell malignancies. Br. J. Clin. Pharmacol., 2015. Epub Jan. 25
Vo, TT, Fruman, DA. INPP4B is a tumor suppressor in the context of PTEN deficiency. 2015. Cancer Discov. 5: 697-700.
Walsh, CM, Fruman, DA. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. 2014. J. Clin. Invest., 124: 3688-90.
Fruman, DA, Cantley, LC. Idelalisib: a PI3K delta inhibitor for B cell malignancies. 2014. New Engl. J. Med., 370: 1061-2.
Fruman, DA, Rommel, C. PI3K and cancer: lessons, challenges, and opportunities. 2014. Nat. Rev. Drug Discov., 13:140-56.
Walsh, CM, Fruman, DA. Too much of a good thing: immunodeficiency due to hyperactive PI3K signaling. 2014. J. Clin. Invest., 124: 3688-90
Conley, ME, Fruman, DA. Can cancer drugs treat immunodeficiency? 2013. Science, 342:814-5.
Yea, SS, Fruman, DA. Achieving cancer cell death with PI3K/mTOR-targeted therapies. 2013. Ann. NY Acad. Sci., 1280: 15-18.
Limon, JJ, Fruman, DA. Akt and mTOR in B cell activation and differentiation. 2012. Front. Immunol., 3: 228.
So, L, Fruman, DA. PI 3-kinase signaling in the immune system. 2012. Biochem J, 442: 465-481
Janes, MR, Fruman, DA. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. In Thomas Weichhart, editor: Methods in Molecular Biology volume entitled “mTOR: Methods and Protocols”. 2012. Meth. Mol. Biol. 821: 251-65.
2011 and earlier
Research Papers
Zeng, Z, Shi, YX, Tsao, T, Qui, Y, Kornblau, SM, Baggerly, KA, Liu, W, Jessen, K, Liu, Y, Kantarjian, H, Rommel, C, Fruman, DA, Andreeff, M, Konopleva, M. Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. 2012. Blood, 120: 2679-89.
Soyfoo, MS, Konno, A, Bolaky, N, Oak, JS, Fruman, DA, Nicaise, C, Takiguchi, M, Delporte, C. Link between inflammation and aquaporin-5 distribution in submandibular gland in Sjögren’s syndrome? 2012. Oral Diseases, 18: 568-574.
Romero Rosales, KR, Singh, G, Wu, K, Chen, J, Janes, MR, Lilly, MB, Peralta, ER, Siskind, LJ, Bennett, MJ, Fruman, DA, Edinger, AL. Sphingolipid-based drugs selectively kill cancer cells by downregulating nutrient transporters. 2011. Biochem. J., 439: 299-311.
Casey, SC, Nelson, EL, Turco, GM, Janes, MR, Fruman, DA, Blumberg, B. B-1 Cell Lymphoma in Mice Lacking the Steroid and Xenobiotic Receptor, SXR. 2011. Mol. Endocrinol. 25: 933-43.
Chen, J, Blanc, C, Peng, SL, Fruman, DA. Foxo1 regulates marginal zone B cell development. 2010 Eur. J. Immunol. 40: 1890-1896.
Janes, MR, Limon, JJ, So, L, Chen, J, Lim, RJ, Chavez, MA, Vu, C, Lilly, MB, Mallya, S, Ong, ST, Konopleva, M, Martin, MB, Ren, P, Liu, Y, Rommel, C, Fruman, DA. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. 2010. Nat. Med. 16: 205-213.
Mouta-Bellum, C, Kirov, A, Miceli-Libby, L, Mancini, ML, Petrova, TV, Liaw, L, Prudovsky, I, Thorpe, PE, Miura, N, Cantley, LC, Alitalo, K, Fruman, DA, Vary, CP. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85a, p55a, and p50a. 2009. Dev. Dynamics 238: 2670-2679.
Oak, JS, Chen, J, Peralta, RQ, Deane, JA, Fruman, DA. The p85b regulatory subunit of phosphoinositide 3-kinase has unique and redundant functions in B cells. 2009. Autoimmunity, 42: 447-458.
Alcazar, I, Barber, DF, Cortes, I, Fruman, DA, Carrera, AC. p85b phosphoinositide 3-kinase regulates CD28 co-receptor function. 2009. Blood, 113: 3198-208.
Kharas, MG, Janes, MR, Scarfone, VM, Lilly, MB, Knight, ZA, Shokat, KS, Fruman, DA. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of BCR-ABL+ leukemia cells. 2008. J. Clin. Invest., 118: 3038-50.
Fabre, S, Carrette, F, Chen, J, Lang, C, Semichon, M, Denoyelle, C, Lazar, V, Cagnard, N, Dubart-Kupperschmitt, A, Mangeney, M, Fruman, DA, Bismuth, G. FOXO1 regulates L-selectin and a network of human T-cell homing molecules downstream of PI3K. 2008. J. Immunol., 181: 2980-9.
De Souza, AJ, Oak, JS, Jordanhazy, R, DeKruyff, RH, Fruman, DA, Kane, LP. Tim-1-mediated T cell activation requires recruitment and activation of PI 3-Kinase. 2008. J. Immunol., 180: 6518-26.
Yusuf, I, Kharas, MG, Chen, J, Peralta, RQ, Maruniak, A, Sareen, P, Tomayko, M, Shlomchik, MJ, Yang, VW, Kaestner, KH, Fruman, DA. KLF4 is a FOXO target gene that suppresses B cell proliferation. 2008. Int. Immunol., 20: 671-81.
Donahue, AC, Fruman, DA. Distinct signaling mechanisms activate the target of rapamycin in response to different B cell stimuli. 2007. Eur. J. Immunol., 37: 2923-36.
Matheu, MP, Deane, JA, Parker, I, Fruman, DA*, Cahalan, MD*. Class IA phosphoinositide 3-kinase signaling is critical for basal lymphocyte motility in the lymph node. 2007. J. Immunol., 179: 2261-9. * Equal
Deane, JA, Kharas, MG, Oak, JS, Stiles, LN, Luo, J, Moore, TI, Ji, H, Rommel, C, Cantley, LC, Lane, TE, Fruman, DA. T cell function is partially maintained in the absence of class IA phosphoinositide 3-kinase regulatory isoforms. 2007. Blood, 109: 2894-902.
Kharas, MG, Yusuf, I, Scarfone, VM, Yang, VW, Segre, JA, Huettner, CS, Fruman, DA. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. 2007. Blood, 109: 747-55.
Oak, JS, Deane, JA, Kharas, MG, Luo, J, Lane, TE, Cantley, LC, Fruman, DA. Sjögren’s Syndrome-like disease in mice with T cells lacking phosphoinositide 3-kinase. 2006. Proc. Natl. Acad. Sci. USA. 103: 16882-7.
Chen, J, Yusuf, I, Andersen, HM, Fruman, DA. FOXO transcription factors cooperate with dEF1 to activate growth suppressive genes in B lymphocytes. 2006. J. Immunol., 176: 2711-21.
Cruz, R, Hedden, L, Boyer, D, Kharas, MG, Fruman, DA, Lee-Fruman, KK. S6 kinase 2 potentiates interleukin-3-driven cell proliferation. 2005. J. Leuk. Biol., 78: 1378-85.
Kharas, MG, Fruman, DA. Abl oncogenes and PI3K: Mechanisms of activation and downstream effectors. 2005. Cancer Res., 65: 2047-53.
Brachmann, S, Yballe, CM, DiFiore, PP, Deane, JA, Fruman, DA, Thomas, SM, Cantley, LC. The role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. 2005. Mol. Cell. Biol., 25: 2593-606.
Zhu, X, Hart, R, Kim, JW, Lee, SY, Chang, MS, Cao, YA, Mock, D, Ke, E, Saunders, B, Alexander, A, Grossoehme, J, Lin, KM, Yan, Z, Hsueh, R, Fruman, DA, Subramaniam, S, Sternweis, P, Simon, MI Choi, S. Analysis of the major patterns of B cell gene expression changes in response to short-term stimulation with 33 single ligands. 2004. J. Immunol., 173: 7141–7149.
Donahue, AC, Hess, KL, Ng, KL, Fruman, DA. Altered splenic B cell subset development in mice lacking phosphoinositide 3-kinase p85alpha. 2004. Int. Immunol., 16: 1789-98.
Hess, KL, Donahue, AC, Ng, KL, Moore, TI, Oak, J, Fruman, DA. The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses. 2004. Eur. J. Immunol., 34: 2968-76.
Yusuf, I, Zhu, X, Kharas, MG, Chen, J, Fruman, DA. Optimal B cell proliferation requires phosphoinositide 3-kinase-dependent inactivation of FOXO transcription factors. 2004. Blood, 104: 784-7.
Kharas, MG, Deane, JA, Wong, S, O’Bosky, KR, Rosenberg, N, Witte, ON, Fruman, DA. Phosphoinositide 3-kinase is essential for Abl oncogene mediated transformation of B lineage cells. 2004. Blood, 103: 4268-75.
Deane, JA, Trifilo, MJ, Yballe, CM, Choi, S, Lane, TE, Fruman, DA. Enhanced T cell proliferation in mice lacking the p85b subunit of phosphoinositide 3-kinase. 2004. J. Immunol., 172: 6615-25.
Ueki, K, Fruman, DA, Yballe, CM, Fassaur, M, Klein, J, Asano, T, Cantley, LC, Kahn, CR. Positive and negative roles of p85alpha and p85beta regulatory subunits of phosphoinositide 3-kinase in insulin signaling. 2003. J. Biol. Chem., 278: 48453-66.
Maeda, N, Inoshima, Y, Fruman, DA, Brachmann,SM, H Fan. Transformation of mouse fibroblasts by Jaagsiekte sheep retrovirus envelope does not require phosphoinositide 3-kinase. 2003. J. Virol., 77: 9951-9.
Yusuf, I, Fruman, DA. Regulation of quiescence in lymphocytes. 2003. Trends Immunol., 24:380-6.
Donahue, AC, Fruman, DA. Proliferation and survival of activated B cells requires sustained antigen receptor signaling and phosphoinositide 3-kinase activation. 2003. J. Immunol. 170: 5851-60.
Hallman, D, Trumper, K, Trusheim, H, Ueki, K, Kahn, CR, Cantley, LC, Fruman, DA, Horsch, D. Altered signaling and cell cycle regulation in embryonal stem cells with a disruption of the gene for phosphoinositide 3-kinase regulatory subunit p85a. 2003. J. Biol. Chem. 278: 5099-108.
Gilman AG, Simon MI, Bourne HR, Harris BA, Long R, Ross EM, Stull JT, Taussig R, Bourne HR, Arkin AP, Cobb MH, Cyster JG, Devreotes PN, Ferrell JE, Fruman D, Gold M, Weiss A, Stull JT, Berridge MJ, Cantley LC, Catterall WA, Coughlin SR, Olson EN, Smith TF, Brugge JS, Botstein D, Dixon JE, Hunter T, Lefkowitz RJ, Pawson AJ, Sternberg PW, Varmus H, Subramaniam S, Sinkovits RS, Li J, Mock D, Ning Y, Saunders B, Sternweis PC, Hilgemann D, Scheuermann RH, DeCamp D, Hsueh R, Lin KM, Ni Y, Seaman WE, Simpson PC, O’Connell TD, Roach T, Simon MI, Choi S, Eversole-Cire P, Fraser I, Mumby MC, Zhao Y, Brekken D, Shu H, Meyer T, Chandy G, Heo WD, Liou J, O’Rourke N, Verghese M, Mumby SM, Han H, Brown HA, Forrester JS, Ivanova P, Milne SB, Casey PJ, Harden TK, Arkin AP, Doyle J, Gray ML, Meyer T, Michnick S, Schmidt MA, Toner M, Tsien RY, Natarajan M, Ranganathan R, Sambrano GR; Participating investigators and scientists of the Alliance for Cellular Signaling. Overview of the Alliance for Cellular Signaling. 2002. Nature, 420: 703-6.
Ueki, K, Fruman, DA, Brachmann, SM, Tseng, Y_H, Cantley, LC, Kahn, CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. 2002. Mol. Cell. Biol. 22: 965-77.
Mauvais-Jarvis, F, Ueki, K, Fruman, DA, Hirschman, MF, Sakamoto, K, Goodyear, LJ, Iannacone, M, Accili, D, Cantley, LC, Kahn, CR. Reduced expression of the murine p85a subunit of phosphoinositide 3-kinase improves insulin signaling and ameliorates diabetes. 2002. J. Clin. Invest. 109: 141-9.
Fruman, DA, Ferl, GZ, An, SS, Donahue, AC, Satterthwaite, AB, Witte, ON. Phosphoinositide 3-kinase and Bruton’s tyrosine kinase regulate overlapping sets of genes in B lymphocytes. 2002. Proc. Natl. Acad. Sci. USA 99: 359-64.
Fruman, DA, Mauvais-Jarvis, F, Pollard, DA, Brazil, D, Bronson, RT, Kahn, CR, Cantley, LC. Hypoglycemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85a. 2000. Nature Genet. 26: 379-82.
Fruman, DA, Snapper, SB, Yballe, CM, Yu, JY, Davidson, L, Alt, FW, Cantley, LC. Impaired B cell development and function in the absence of phosphoinositide 3-kinase p85a. 1999. Science 283: 393-7.
Invited Review Articles, Commentaries and Book Chapters
Fruman, DA, Rommel, C. PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. 2011. Cancer Discovery 1: 562-72.
Janes, MR, Fruman, DA. The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia. 2011. Methods Mol Biol. 821: 251-65.
Beagle, B, Fruman, DA. Lipid kinase cousins cooperate to promote cancer. 2011. Cancer Cell, 19: 693-5.
Yea, SS, Fruman, DA. New mTOR targets Grb attention. 2011. Science, 332: 1270-1.
Vu, C, Fruman, DA. Targeting TOR signaling in leukemia and lymphoma. 2010. Clin. Cancer Res. 16: 5374-80.
Fruman, DA. Regulatory subunits of class IA PI3K. In Peter K. Vogt, Christian Rommel, and Bart Vanhaesebroeck, editors: CTMI volume on “Phosphoinositide 3-kinase in health and disease”, 2010. Pp. 225-244. Also available on PubMed as Curr. Top. Microbiol. Immunol., 346: 225-244 (2011).
Okkenhaug, K, Fruman, DA. PI3Ks in lymphocyte signaling and development. In Peter K. Vogt, Christian Rommel, and Bart Vanhaesebroeck, editors: CTMI volume on “Phosphoinositide 3-kinase in health and disease”, Springer-Verlag, 2010. Pp. 57-85. Also available on PubMed as Curr. Top. Microbiol. Immunol., 346: 57-85 (2011).
Limon, JJ, Fruman, DA. B cell receptor signaling: Picky about PI3Ks. 2010. Sci. Signal. 3: pe25.
Janes, MR, Fruman, DA. Targeting TOR dependency in cancer. 2010. Oncotarget 1: 69-76.
Fruman, DA. Phosphoinositide 3-kinases. 2009. In Ralph A. Bradshaw and Edward A. Dennis, editors: Handbook of Cell Signaling 2nd edition, Oxford:Academic Press, 2009, pp. 1049-1060.
Janes, MR, Fruman, DA. Immune regulation by rapamycin: moving beyond T cells. 2009. Sci. Signal. 2: pe25.
Fruman, DA, Edinger, AL. Cancer therapy: staying current with AMP kinase. 2008. Biochem. J. 412: e3-5.
Fruman, DA, Bismuth, G. Fine tuning the immune response with PI3K. 2009. Immunol. Rev. 228: 253-272.
Oak, JS, Matheu, MP, Parker, I, Cahalan, MD, Fruman, DA. Lymphocyte cell motility: the twisting, turning tale of phosphoinositide 3-kinase. 2007. Biochem. Soc. Trans., 35: 1109-13.
Donahue, AC, Kharas, MG, Fruman, DA. Measuring phosphoAkt and other PI3K-regulated phosphoproteins in primary lymphocytes. 2007. Methods Enzymol.,434: 131-54.
Oak, JS, Fruman, DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. 2007. Autoimmunity, 40(6): 433-41.
Fruman, DA. The role of class I phosphoinositide 3-kinase in T cell function and autoimmunity. 2007 Biochem. Soc. Trans., 35(2): 177-80.
Fruman, DA. Bursting with PIP3. 2005. Blood, 106:1139-40.
Fruman, DA. PI3K and its targets in B cell and T cell signaling. 2004. Curr Opin. Immunol., 16: 314-20.
Fruman, DA. Towards and understanding of isoform specificity in phosphoinositide 3-kinase signaling in lymphocytes. 2004. Biochem. Soc. Trans. 32: 315-9.
Donahue, AC, Fruman, DA. PI3K signaling controls cell fate at many points in B lymphocyte development and activation. 2004. Semin. Cell Dev. Biol., 15: 183-97.
Deane, JD, Fruman, DA. Phosphoinositide 3-kinase: diverse roles in immune cell activation. 2004. Annu. Rev. Immunol., 22: 563-98.
Fruman, DA. Phosphoinositide 3-kinases. 2003. In Handbook of Cellular Signaling. Ed. Bradshaw, RA, Dennis, E, Academic Press, CA. Vol. 2, pp. 135-41.
Fruman, DA, Cantley, LC. Phosphoinositide 3-kinase in immunological systems. 2002. Semin. Immunol., 14: 7-18.
Fruman, DA, Satterthwaite, AB, Witte, ON. Xid-like phenotypes: a B cell signalosome takes shape. 2000. Immunity 13: 1-3.